White blood cells could predict AMD

Article

An increased level of white blood cells can predict the risk of developing early age-related macular degeneration (AMD), according to findings published recently in the American Journal of Epidemiology.

An increased level of white blood cells can predict the risk of developing early age-related macular degeneration (AMD), according to findings published recently in the American Journal of Epidemiology.

The Blue Mountains Eye Study, carried out by Anoop Shankar, MD and colleagues, looked at the association between markers of systemic inflammation and the development of AMD. The baseline white blood cell level was measured in 3,654 subjects aged between 49 and 97, who were then followed for up to 10 years for the development of both early and late AMD.

The results showed that subjects in the highest white blood cell count tertile (>6.7 billion cells/L) were 85% more likely to develop AMD than those in the lowest tertile (no greater than 5.5 billion cells/L). This was seen in all types of early AMD lesions, including soft indistinct or reticular drusen and incident pigmentary abnormalities, and also in gender and smoking subgroup analyses.

The study concluded that an increased white blood cell count can be used to identify individuals who are at greater risk of developing AMD, independent of possible confounding factors such as smoking and gender. The researchers claim that the findings provide important evidence of a link between inflammation, thought to play a key role in the pathogenesis of AMD and AMD development.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.